In Vitro and In Vivo Hydrolytic Degradation Behaviors of a Drug-Delivery System Based on the Blend of PEG and PLA Copolymers
November 27, 2023
November 27, 2023
MedinCell applauds Teva and Royalty Pharma collaboration to further accelerate olanzapine LAI program
November 13, 2023
November 13, 2023
MedinCell at the 2023 Jefferies Global Healthcare Conference -London, 14-16 November
November 6, 2023
November 6, 2023
MedinCell and the European Investment Bank (EIB) have replaced a financial covenant of their ongoing loan agreement to better fit with MedinCell business model
MedinCell announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total knee replacement
August 31, 2023
August 31, 2023
Participation terms in the Combined General Meeting
August 21, 2023
August 21, 2023
Contacts
Medincell
David Heuzé
Head of Corporate and Financial Communications, and ESG
